论文部分内容阅读
目的:本研究旨在探讨促红细胞生成素(EPO)对急性病毒性心肌炎的临床疗效及不良反应。方法:2006年5月-2008年5月40例急性病毒性心肌炎患者随机分成治疗组(n=20)及对照组(n=20)。对照组采用常规使用抗生素,病毒唑,β受体阻滞剂等药物,静脉极化液治疗,治疗组在对照组同样治疗方法基础上皮下注射EPO 100 IU/kg,每周2次,疗程30 d。结果:治疗组EPO治疗前后相比肌钙蛋白峰值降低且恢复正常时间缩短;心律失常,急性左心力衰竭(心衰)发生率明显降低,有显著改善(P<0.05),组间比较治疗组较对照组显著改善(P<0.05)。结论:EPO能改善急性病毒性心肌炎临床症状,减轻心肌损伤,降低心律失常、急性左心衰发生率。
Objective: This study aimed to investigate the clinical efficacy and adverse reactions of erythropoietin (EPO) in acute viral myocarditis. Methods: From May 2006 to May 2008, 40 patients with acute viral myocarditis were randomly divided into treatment group (n = 20) and control group (n = 20). Patients in the control group were treated with routine antibiotics, ribavirin, β-blockers and other drugs and intravenous fluids. The treatment group received 100 IU / kg of EPO subcutaneously on the basis of the same treatment in the control group twice a week for 30 days d. Results: Compared with the control group, the peak value of troponin before and after EPO treatment was decreased and the recovery time was shortened. The incidence of arrhythmia and acute left heart failure (HF) was significantly decreased (P <0.05) Compared with the control group significantly improved (P <0.05). Conclusion: EPO can improve the clinical symptoms of acute viral myocarditis, reduce myocardial injury, reduce the incidence of arrhythmia and acute left heart failure.